Ambarella Inc vs Centene Corp — how do they compare? Ambarella Inc trades at $75.05 (market cap $3.39B), while Centene Corp trades at $67.49 (market cap $33.26B). The key difference: Centene Corp is far larger — about 9.8× Ambarella Inc's market cap, and Centene Corp is trading nearer its 52-week high, Ambarella Inc nearer its low. Which is the better fit depends on your goals.
| AMBA | CNC | |
|---|---|---|
Market Cap | $3.39B | $33.26B |
Sector | Technology | Health |
52-Week High | $95.51 | $68.34 |
52-Week Low | $48.65 | $25.21 |
Enterprise Value | $3.13B | $25.89B |
Signals from Pluang's Aura AI — not financial advice
Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.
Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.
Centene (CNC) trades at $67.35, down 0.37% on the day, with a bullish technical signal from moving averages. The stock shows attractive valuation ratios, including a P/E of 8.06 and P/S of 0.17, but faces profitability challenges with a negative net income margin of -3.25% for 2025. Recent positive developments include the renewal of a key Illinois Medicaid contract and consistent earnings beats in recent quarters, supporting a strong analyst consensus with 61% buy ratings.
The outlook for CNC hinges on successful margin recovery initiatives and cost management. Investment opportunities lie in its undervalued metrics and stable revenue base, but risks include persistent negative profitability, regulatory pressures in healthcare, and execution challenges in improving medical cost controls. The consensus price target of $63.36 suggests limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →